Evofem Biosciences, Inc.
EVFM
$0.01
$0.00-8.54%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -296.02% | 277.69% | 12.05% | -286.61% | 131.48% |
| Total Depreciation and Amortization | 3.74% | -9.32% | -12.59% | -49.25% | -26.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.57% | 162.43% | 6.35% | 108.19% | -317.40% |
| Change in Net Operating Assets | 256.51% | -433.28% | 172.13% | -133.18% | 314.19% |
| Cash from Operations | 7,322.58% | -90.77% | 111.51% | -621.25% | 123.26% |
| Capital Expenditure | 33.33% | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 89.73% |
| Cash from Investing | 33.33% | -- | 100.00% | 96.49% | -23.91% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -79.14% | -13.93% | 1.61% | -83.70% | 49.44% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -71.72% | -18.85% | -109.53% | 1,996.30% | -105.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 787.40% | -384.78% | 125.48% | -198.10% | 1,836.84% |